Isatoribine
Alternative Names: 7-thia-8-oxoguanosine; 7T80G; ANA-245; ICN-10146; ICN25; Immunosine; Immusine; KN 25; N10146; N12143; N14316; NARI-10146; ThiaoxoguanosineLatest Information Update: 18 Jul 2018
At a glance
- Originator sanofi-aventis; Valeant Pharmaceuticals International
- Developer Anadys Pharmaceuticals
- Class Antineoplastics; Antivirals; Immunotherapies; Purine nucleosides; Small molecules
- Mechanism of Action Interferon alpha stimulants; Natural killer cell stimulants; Toll-like receptor 7 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Cancer; Hepatitis C
Most Recent Events
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
- 04 Nov 2004 Data presented at the 55th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2004) have been added to the adverse events , and Viral Infections pharmacodynamics and therapeutic trials sections
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form sanofi-aventis